Pelvic inflammatory disease: review of treatment options
H B Peterson1, E I Galaid, J M Zenilman
1U.S. Department of Health and Human Services, Atlanta, Georgia.
Abstract:
Decisions regarding appropriate antibiotic therapy for treatment of pelvic inflammatory disease (PID) are complicated by an incomplete understanding of the syndrome. Further, the lack of data on laparoscopic diagnosis and cure of PID severely limits our ability to interpret data on therapy outcome. Validation studies of the treatment regimens recommended by the Centers for Disease Control in the 1985 treatment guidelines for sexually transmitted diseases (STDs) suggest that both the cefoxitin/doxycycline and clindamycin/aminoglycoside combination regimens result in consistently high rates of clinical evidence of cure. The 1989 STD treatment guidelines were based on these studies and on available data regarding newer treatment regimens. Empiric, broad-spectrum therapy remains the treatment of choice. The two regimens recommended for inpatient therapy in 1989 are similar to those recommended in 1985. The recommendation for management of ambulatory patients has been substantially changed, however, because of increasing resistance of Neisseria gonorrhoeae to penicillin.
Insights
Treatment guidelines for pelvic inflammatory disease (PID) are evolving due to incomplete understanding and antibiotic resistance. Current recommendations favor broad-spectrum antibiotic therapy for both inpatient and ambulatory cases.
Area of Science:
- Infectious Diseases
- Gynecology
- Microbiology
Background:
- Pelvic inflammatory disease (PID) treatment decisions are complex due to incomplete understanding of the syndrome.
- Limited data on laparoscopic diagnosis and cure of PID hinder interpretation of therapy outcomes.
- Increasing resistance of Neisseria gonorrhoeae to penicillin impacts treatment strategies.
Purpose of the Study:
- To review and update antibiotic therapy recommendations for pelvic inflammatory disease (PID).
- To evaluate the effectiveness of current and newer treatment regimens based on available data.
- To address challenges in PID management, including diagnostic limitations and evolving microbial resistance.
Main Methods:
- Review of validation studies for recommended antibiotic regimens.
- Analysis of data from the 1985 and 1989 Centers for Disease Control (CDC) sexually transmitted diseases (STDs) treatment guidelines.
- Assessment of clinical cure rates for cefoxitin/doxycycline and clindamycin/aminoglycoside regimens.
Main Results:
- Cefoxitin/doxycycline and clindamycin/aminoglycoside regimens show consistently high clinical cure rates for PID.
- Empiric, broad-spectrum antibiotic therapy remains the preferred treatment approach.
- 1989 inpatient therapy recommendations are similar to 1985, but ambulatory management recommendations have changed significantly.
Conclusions:
- Current antibiotic regimens demonstrate high efficacy in treating pelvic inflammatory disease (PID).
- Empiric broad-spectrum therapy is crucial for effective PID management.
- Adjustments in ambulatory PID treatment are necessary due to Neisseria gonorrhoeae penicillin resistance.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Intrauterine Drug Delivery Systems
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Calculi III: Medical Management


